PMID- 35522256
OWN - NLM
STAT- MEDLINE
DCOM- 20220613
LR  - 20220716
IS  - 1751-7176 (Electronic)
IS  - 1524-6175 (Print)
IS  - 1524-6175 (Linking)
VI  - 24
IP  - 6
DP  - 2022 Jun
TI  - Higher plasma renin activity is associated with increased kidney damage risk in 
      patients with hypertension and glucose metabolic disorders.
PG  - 750-759
LID - 10.1111/jch.14492 [doi]
AB  - The impact of renin on kidney remain unclear among hypertensives with glucose 
      metabolic disorders (GMD). We aimed to evaluate the association between plasma 
      renin activity (PRA) and kidney damage in hypertensive patients with GMD. 
      Overall, 2033 inpatients with hypertension and GMD free of chronic kidney disease 
      (CKD) at baseline were included. CKD was defined using estimated glomerular 
      filtration rate (eGFR) and urine protein. PRA was treated as continuous variable, 
      and also dichotomized as high (>/=0.65) or low (< 0.65) groups. The association of 
      PRA with incident CKD was evaluated using multivariable Cox model controlling for 
      antihypertensive medications and baseline aldosterone, and traditional 
      parameters. Subgroup and interaction analyses were performed to evaluate 
      heterogeneity. During a median follow-up of 31 months, 291 participants developed 
      CKD. The incidence was higher in high-renin group than that in low-renin group 
      (54.6 vs 36.6/1000 person-years). Significant association was observed between 
      PRA and incident CKD, and the association was mainly driven by an increased risk 
      for proteinuria. Each standard deviation increment in log-transformed PRA was 
      associated with 16.7% increased risk of proteinuria (hazard ratio = 1.167, 
      P = .03); compared with low-renin group, there was 78.4% increased risk for 
      high-renin group (hazard ratio = 1.784, P = .001). Nonlinear associations were 
      observed between PRA and kidney damage. Higher PRA is associated with greater 
      risk of incident kidney damage, especially for positive proteinuria, in patients 
      with coexistence of hypertension and diabetes, independent of aldosterone. In 
      this patient population with high risk for kidney damage, PRA may serve as an 
      important predictor.
CI  - (c) 2022 The Authors. The Journal of Clinical Hypertension published by Wiley 
      Periodicals LLC.
FAU - Lin, Mengyue
AU  - Lin M
AUID- ORCID: 0000-0002-0389-0331
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Xinjiang Hypertension Institute; National Health Committee, Key Laboratory of 
      Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous 
      Region "Hypertension Research Laboratory", Xinjiang Clinical Medical Research 
      Center for Hypertension (Cardio-Cerebrovascular) Diseases, Urumqi, China.
FAU - Heizhati, Mulalibieke
AU  - Heizhati M
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Xinjiang Hypertension Institute; National Health Committee, Key Laboratory of 
      Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous 
      Region "Hypertension Research Laboratory", Xinjiang Clinical Medical Research 
      Center for Hypertension (Cardio-Cerebrovascular) Diseases, Urumqi, China.
FAU - Gan, Lin
AU  - Gan L
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Xinjiang Hypertension Institute; National Health Committee, Key Laboratory of 
      Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous 
      Region "Hypertension Research Laboratory", Xinjiang Clinical Medical Research 
      Center for Hypertension (Cardio-Cerebrovascular) Diseases, Urumqi, China.
FAU - Hong, Jing
AU  - Hong J
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Xinjiang Hypertension Institute; National Health Committee, Key Laboratory of 
      Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous 
      Region "Hypertension Research Laboratory", Xinjiang Clinical Medical Research 
      Center for Hypertension (Cardio-Cerebrovascular) Diseases, Urumqi, China.
FAU - Wu, Ting
AU  - Wu T
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Xinjiang Hypertension Institute; National Health Committee, Key Laboratory of 
      Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous 
      Region "Hypertension Research Laboratory", Xinjiang Clinical Medical Research 
      Center for Hypertension (Cardio-Cerebrovascular) Diseases, Urumqi, China.
FAU - Xiamili, Zuhere
AU  - Xiamili Z
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Xinjiang Hypertension Institute; National Health Committee, Key Laboratory of 
      Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous 
      Region "Hypertension Research Laboratory", Xinjiang Clinical Medical Research 
      Center for Hypertension (Cardio-Cerebrovascular) Diseases, Urumqi, China.
FAU - Tong, Ling
AU  - Tong L
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Xinjiang Hypertension Institute; National Health Committee, Key Laboratory of 
      Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous 
      Region "Hypertension Research Laboratory", Xinjiang Clinical Medical Research 
      Center for Hypertension (Cardio-Cerebrovascular) Diseases, Urumqi, China.
FAU - Lin, Yue
AU  - Lin Y
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Xinjiang Hypertension Institute; National Health Committee, Key Laboratory of 
      Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous 
      Region "Hypertension Research Laboratory", Xinjiang Clinical Medical Research 
      Center for Hypertension (Cardio-Cerebrovascular) Diseases, Urumqi, China.
FAU - Li, Nanfang
AU  - Li N
AUID- ORCID: 0000-0003-1505-8566
AD  - Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Xinjiang Hypertension Institute; National Health Committee, Key Laboratory of 
      Hypertension Clinical Research, Key Laboratory of Xinjiang Uygur Autonomous 
      Region "Hypertension Research Laboratory", Xinjiang Clinical Medical Research 
      Center for Hypertension (Cardio-Cerebrovascular) Diseases, Urumqi, China.
LA  - eng
GR  - 2020-RW330-002/Non-profit Central Research Institute Fund of Chinese Academy of 
      Medical Sciences/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220506
PL  - United States
TA  - J Clin Hypertens (Greenwich)
JT  - Journal of clinical hypertension (Greenwich, Conn.)
JID - 100888554
RN  - 4964P6T9RB (Aldosterone)
RN  - EC 3.4.23.15 (Renin)
SB  - IM
MH  - Aldosterone
MH  - *Glucose Metabolism Disorders/complications/metabolism
MH  - Humans
MH  - *Hypertension/complications/epidemiology
MH  - Kidney
MH  - Proteinuria/complications
MH  - *Renal Insufficiency, Chronic/complications/epidemiology
MH  - Renin
PMC - PMC9180335
OTO - NOTNLM
OT  - chronic kidney disease
OT  - diabetes
OT  - hypertension
OT  - renin
OT  - risk factors
COIS- The authors have declared that no conflict of interest exists.
EDAT- 2022/05/07 06:00
MHDA- 2022/06/14 06:00
PMCR- 2022/05/06
CRDT- 2022/05/06 11:23
PHST- 2022/04/20 00:00 [revised]
PHST- 2022/03/27 00:00 [received]
PHST- 2022/04/20 00:00 [accepted]
PHST- 2022/05/07 06:00 [pubmed]
PHST- 2022/06/14 06:00 [medline]
PHST- 2022/05/06 11:23 [entrez]
PHST- 2022/05/06 00:00 [pmc-release]
AID - JCH14492 [pii]
AID - 10.1111/jch.14492 [doi]
PST - ppublish
SO  - J Clin Hypertens (Greenwich). 2022 Jun;24(6):750-759. doi: 10.1111/jch.14492. 
      Epub 2022 May 6.